ContraFect Doses First Patient in Phase 1b/2 Study for Exebacase; Shares Rise 66%
Biotechnology company, ContraFect Corporation (Nasdaq: CFRX), has dosed the first patient in its Phase 1b/2 studyof its lead candidate, exebacase.
Exebacase is being evaluated in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee.
ContraFect’s share price rose 66% following the news.
Highlights
ContraFect’s study is a randomized, double-blind, placebo-controlled clinical study conducted in France to assess the safety, pharmacokinetics (PK), and efficacy of exebacase in patients with chronic PJIs of the knee due to Staphylococcus aureus ( aureus) or Coagulase-Negative Staphylococci (CoNS).
Patients entering the study will be randomized 3:1 to either exebacase or placebo, with all patients receiving the study drug in the setting of a DAIR Procedure.Surgical revision of an infected prosthesis can be a debilitating and expensive procedure.
About ContraFect Corporation
ContraFect is a biotechnology company focused on the discovery and development of Direct Lytic Agents (DLAs) as treatments for life threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. ContraFect is working to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. The company has completed a Phase 2 clinical trial evaluating its lead candidate, exebacase. Exebacase has been granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
